Kintara Total Liab vs Net Working Capital Analysis
| KTRA Stock | USD 0.17 0.01 6.25% |
Kintara Therapeutics financial indicator trend analysis is infinitely more than just investigating Kintara Therapeutics recent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Kintara Therapeutics is a good investment. Please check the relationship between Kintara Therapeutics Total Liab and its Net Working Capital accounts. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Kintara Therapeutics. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in metropolitan statistical area. For information on how to trade Kintara Stock refer to our How to Trade Kintara Stock guide.
Total Liab vs Net Working Capital
Total Liab vs Net Working Capital Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Kintara Therapeutics Total Liab account and Net Working Capital. At this time, the significance of the direction appears to have weak contrarian relationship.
The correlation between Kintara Therapeutics' Total Liab and Net Working Capital is -0.04. Overlapping area represents the amount of variation of Total Liab that can explain the historical movement of Net Working Capital in the same time period over historical financial statements of Kintara Therapeutics, assuming nothing else is changed. The correlation between historical values of Kintara Therapeutics' Total Liab and Net Working Capital is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Total Liab of Kintara Therapeutics are associated (or correlated) with its Net Working Capital. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Net Working Capital has no effect on the direction of Total Liab i.e., Kintara Therapeutics' Total Liab and Net Working Capital go up and down completely randomly.
Correlation Coefficient | -0.04 |
| Relationship Direction | Negative |
| Relationship Strength | Insignificant |
Total Liab
The total amount of all liabilities that a company has, including both short-term and long-term liabilities.Net Working Capital
Most indicators from Kintara Therapeutics' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Kintara Therapeutics current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Kintara Therapeutics. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in metropolitan statistical area. For information on how to trade Kintara Stock refer to our How to Trade Kintara Stock guide.At present, Kintara Therapeutics' Enterprise Value Over EBITDA is projected to increase significantly based on the last few years of reporting. The current year's Enterprise Value Multiple is expected to grow to 0.0005, whereas Selling General Administrative is forecasted to decline to about 4.7 M.
| 2021 | 2023 | 2024 (projected) | Research Development | 15.2M | 8.4M | 8.0M | Depreciation And Amortization | 60K | 69K | 72.5K |
Kintara Therapeutics fundamental ratios Correlations
Click cells to compare fundamentals
Kintara Therapeutics Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Kintara Therapeutics fundamental ratios Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Total Assets | 2.9M | 13.5M | 15.9M | 4.0M | 4.6M | 5.8M | |
| Total Current Liabilities | 2.7M | 2.8M | 4.0M | 3.1M | 3.5M | 3.7M | |
| Total Stockholder Equity | 263.2K | 10.6M | 11.8M | 731K | 840.7K | 798.6K | |
| Net Debt | (2.4M) | (10.5M) | (11.8M) | (1.5M) | (1.4M) | (1.5M) | |
| Retained Earnings | (69.7M) | (111.2M) | (136.4M) | (151.4M) | (136.2M) | (129.4M) | |
| Accounts Payable | 2.0M | 2.2M | 3.3M | 2.8M | 3.2M | 3.4M | |
| Cash | 2.4M | 10.5M | 11.8M | 1.5M | 1.8M | 1.7M | |
| Cash And Short Term Investments | 2.4M | 10.5M | 11.8M | 1.5M | 1.8M | 1.7M | |
| Common Stock Total Equity | 23.0K | 3.8K | 8.6M | 33K | 38.0K | 36.1K | |
| Common Stock Shares Outstanding | 208.9K | 517.7K | 974K | 1.6M | 1.5M | 777.4K | |
| Liabilities And Stockholders Equity | 2.9M | 13.5M | 15.9M | 4.0M | 4.6M | 5.8M | |
| Non Current Liabilities Total | 2.0M | 182K | 163K | 166K | 149.4K | 141.9K | |
| Other Stockholder Equity | 65.1M | 106.8M | 135.5M | 141.4M | 162.7M | 170.8M | |
| Total Liab | 2.7M | 3.0M | 4.2M | 3.2M | 3.7M | 2.3M | |
| Total Current Assets | 2.9M | 11.8M | 13.3M | 3.3M | 3.8M | 5.4M | |
| Common Stock | 11.5K | 33K | 66K | 2K | 2.3K | 2.2K | |
| Net Receivables | 9.4K | 756K | 1.5M | 660K | 759K | 797.0K | |
| Other Current Liab | 663.9K | 561K | 721K | 298K | 342.7K | 310.2K | |
| Other Current Assets | 355.6K | 1.3M | 1.5M | 660K | 759K | 812.1K | |
| Net Tangible Assets | (4.5M) | (4.4M) | (759K) | (9.9M) | (8.9M) | (8.5M) | |
| Non Current Assets Total | 87.1K | 1.8M | 2.7M | 709K | 815.4K | 736.0K | |
| Net Invested Capital | (4.5M) | (4.4M) | (759K) | (9.9M) | (8.9M) | (8.5M) | |
| Net Working Capital | 176.2K | 9.0M | 9.3M | 188K | 169.2K | 160.7K | |
| Capital Stock | 4.8M | 15.0M | 12.6M | 10.6M | 12.2M | 10.6M |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.| MSFT | Microsoft | |
| GM | General Motors | |
| CRM | Salesforce |
Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Kintara Therapeutics. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in metropolitan statistical area. For information on how to trade Kintara Stock refer to our How to Trade Kintara Stock guide.You can also try the Equity Forecasting module to use basic forecasting models to generate price predictions and determine price momentum.
Complementary Tools for Kintara Stock analysis
When running Kintara Therapeutics' price analysis, check to measure Kintara Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Kintara Therapeutics is operating at the current time. Most of Kintara Therapeutics' value examination focuses on studying past and present price action to predict the probability of Kintara Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Kintara Therapeutics' price. Additionally, you may evaluate how the addition of Kintara Therapeutics to your portfolios can decrease your overall portfolio volatility.
| Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine | |
| Analyst Advice Analyst recommendations and target price estimates broken down by several categories | |
| Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges | |
| Portfolio Anywhere Track or share privately all of your investments from the convenience of any device | |
| Idea Breakdown Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes | |
| Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. | |
| Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years | |
| Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules | |
| Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios |
Is Kintara Therapeutics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Kintara Therapeutics. If investors know Kintara will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Kintara Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (5.22) | Return On Assets (1.13) | Return On Equity (3.29) |
The market value of Kintara Therapeutics is measured differently than its book value, which is the value of Kintara that is recorded on the company's balance sheet. Investors also form their own opinion of Kintara Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Kintara Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Kintara Therapeutics' market value can be influenced by many factors that don't directly affect Kintara Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Kintara Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Kintara Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Kintara Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.